

## Terumo announces changes to the names of some businesses within the Cardiac and Vascular Company

Disclosure segments of Blood and Cell Technologies Company to also be revised

**TOKYO, JAPAN – April 1, 2025** – Terumo Corporation (TSE: 4543) today announced that it has changed the names of some of the businesses within the Cardiac and Vascular Company as follows, effective today. The change aligns the business names with their respective business brands, which are being promoted globally. The products and services offered by each business will remain unchanged.

### 1. Change of business name

<b>New Name</b>	Name Before Change	(Reference) Business Brand
<b>Terumo Interventional Systems</b>	Interventional Systems Division	Terumo Interventional Systems
<b>Terumo Neuro</b>	Neurovascular Division	Terumo Neuro
<b>Terumo Aortic</b>	Vascular Graft Division	Terumo Aortic

In addition, the disclosure segments of the Blood and Cell Technologies Company will be revised as follows to reflect the organizational changes implemented by the Company in 2024\*. Terumo will use the revised segments to report financial results, starting from the first quarter of the fiscal year ending March 31, 2026.

### 2. Revision of the disclosure segments of the Blood and Cell Technologies Company

<b>New Segments</b>	Segments Before Change	Main Products
<b>Global Blood Solutions</b>	Blood Center Solutions	Blood bags, Automated blood collection systems, Automated blood processing systems, Pathogen reduction systems, Plasma donation systems
<b>Global Therapy Innovations</b>	Therapeutic Solutions	Apheresis systems, Tubing set
	Cell Therapy Technologies	Cell expansion systems, Fill and finish systems, Welders

## **About Terumo**

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for more than 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.